Market Overview

Analysts Come Out Bullish On Radius Health, Shares Rally

Related RDUS
25 Stocks Moving In Wednesday's Pre-Market Session
Benzinga's Option Alert Recap From March 13
FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the ... (GuruFocus)

Early Wednesday morning, four analyst firms issued notes initiating bullish coverage on Radius Health (NASDAQ: RDUS).

Shares of Radius Health have shot up nearly six percent on the news. The firms respective ratings and price targets are listed below.

  • Canaccord Genuity - Buy, $21
  • Cowen & Company - Outperform, N/A
  • Cantor Fitzgerald - Buy, $20
  • Jefferies - Buy, $17

The average of these price targets is $19.33, which represents 53 percent upside to last check price of $12.62.

Latest Ratings for RDUS

Mar 2017H.C. WainwrightReiteratesBuy
May 2016H.C. WainwrightInitiates Coverage onBuy
May 2016Cowen & Co.AssumesOutperform

View More Analyst Ratings for RDUS
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Cantor FitzgeraldAnalyst Color Price Target Initiation Hot Analyst Ratings Movers


Related Articles (RDUS)

View Comments and Join the Discussion!